1. Jersey Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Integrated Diagnostics Holdings plc

Integrated Diagnostics Holdings plc

IDGXF
Integrated Diagnostics Holdings plcUS flagOther OTC
0.59
USD
- -
- -
345.69MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.12
1.43
1.69
1.95
2.52
3.2
3.71
4.43
8.71
6.01
6.87
9.64
13.51
7.91
Basic EPS, GAAP
0.1
0.22
0.24
0.43
0.62
0.84
0.85
0.99
2.35
0.9
0.85
1.82
2.17
1.36
Free Cash Flow per Basic Share
0.31
0.38
0.22
0.58
0.41
0.37
0.8
1.26
3.34
-0.17
0.36
2.26
2.38
1.01
Dividend per Share
0.45
0.39
0.01
0.15
0.63
0.72
0.75
0.75
0.8
2.35
- -
0.05
0.92
- -
Book Value per Share
-0.31
1.79
2.03
2.31
2.31
2.45
2.55
2.79
4.37
3.09
3.92
4.8
6.25
4.81
Tangible Book Value per Share
0.41
0.33
0.56
1.08
1.09
1.21
1.17
1.28
1.89
1.24
2.32
2.85
3.92
2.95
Basic Weighted Avg Shares
600
600
600
600
600
600
600
600
600
600
600
594
581
600
Sales/Revenue/Turnover
672
860
1,015
1,171
1,514
1,921
2,226
2,656
5,225
3,605
4,123
5,720
7,855
4,748
Operating Margin (%)
20.88
30.14
27.91
40.09
36.05
36.15
35.91
38.69
43.77
24.21
19.17
21.22
27.05
20.08
Depreciation Expense
145
116
36
45
62
77
153
185
239
317
401
483
565
438
Net Income, GAAP
62
133
145
260
374
502
511
594
1,413
541
510
1,077
1,262
817
Effective Tax Rate (%)
50.6
42.7
43.54
31.3
31.28
30.73
33.45
37.11
33.14
38.31
36.48
29.95
38.56
33.88
Profit Margin (%)
9.25
15.43
14.28
22.24
24.7
26.13
22.95
22.36
27.04
15.01
12.38
18.84
16.07
17.21
Working Capital
188
129
198
498
494
386
210
351
694
160
687
916
1,254
1,010
LT Debt
1
1
60
120
139
167
358
466
722
1,008
959
1,011
1,195
1,013
Total Equity
1,946
1,805
1,942
2,299
2,314
2,401
2,360
2,426
2,794
2,447
3,101
3,499
4,130
3,552
Return on Invested Capital (%)
3.35
7.55
7.94
13.78
14.52
17.86
18.41
21.02
42.33
13.97
12.8
18.24
23.42
15.68
Return on Capital (%)
-70.65
25.55
11.26
17.71
23
29.93
28.35
27.59
46.01
17.98
17.64
27.92
24.32
26.6
Return on Common Equity (%)
- -
- -
12.67
20.01
26.94
35.14
34.08
37.07
65.71
24.16
24.25
41.4
38.91
32.94

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
220
271
261
LT Borrowings
67
54
54
LT Finance Leases
891
966
959
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
600
600
600
Market Capitalization
6,307
5,562
8,834

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,962
2,371
2,717
Cash, Cash Equivalents & STI
861
984
1,294
Accounts Receivable, Net
570
703
753
Inventories
375
480
462
Total Current Liabilities
1,275
1,574
1,707
Payables & Accruals
- -
- -
- -
ST Debt
220
271
261
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.42%
12.07%
18.03%
Free Cash Flow
55.5%
52.58%
2.93%
Net Income, GAAP
37.43%
39.74%
17.15%
Sales/Revenue/Turnover
26.29%
31.22%
37.34%
Total Cash Common Dividend
- -
- -
1,851.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,171
1,327
- -
- -
5,720
2025
1,583
- -
- -
- -
7,855
2026
2,073
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
1.82
2025
0.42
- -
- -
- -
2.17
2026
0.75
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.92
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Hend El Sherbini
Full Time Employees
6,309
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
12 Castle Street Saint Helier Jersey JE2 3RT
IPO Date
Jun 3, 2019
Website
idhcorp.com
Similar Companies
Mainz Biomed N.V. (QUCY)
Pacific Edge Limited (PEB.NZ)
Avricore Health Inc. (AVCRF)
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
SeqLL Inc. (SQL)
Pacific Edge Limited (PFGTF)
Business
Integrated Diagnostics Holdings plc Integrated Diagnostics Holdings plc (IDGXF) operates as a leading consumer healthcare company providing high-quality medical diagnostic services across the Middle East and Africa. The company offers an extensive portfolio of over 3,000 pathology and molecular diagnostic tests, including immunology, hematology, clinical chemistry, parasitology, toxicology, cytology, surgical pathology, molecular biology, cytogenetics, microbiology, endocrinology, histopathology, and genetics; radiology services such as positron emission tomography-computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-ray, electromyography, electroencephalography, electrocardiogram, and cath lab facilities; and specialized offerings like glucose testing for diabetes, molecular tests for hepatitis, and DNA tests. It serves patients through walk-in and contract segments via seven key brands—Al Borg, Al Borg Scan, and Al Mokhtabar in Egypt; Biolab in Jordan and Saudi Arabia; Ultralab and Al Mokhtabar in Sudan; and Echo-Lab in Nigeria—across more than 600 branches in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan, with headquarters in Cairo, Egypt, and over 40 years of track record at the subsidiary level. Recent developments include the acquisition of an additional 49% stake in Biolab KSA to strengthen Saudi operations; the integration of Cairo RAY for radiotherapy capabilities, enhancing oncology diagnostics; expansion of Al Borg Scan with new branches and American College of Radiology accreditation for nuclear medicine and ultrasound units; renewal of a six-year strategic partnership with Siemens Healthineers for total lab automation; inauguration of a third branch in Riyadh with plans for three more; voluntary delisting from the Egyptian Exchange; and a joint venture agreement with Al Makhbaryoun Al Arab for a greenfield diagnostic venture in Saudi Arabia.

Company News

APIChat

  • seekingalpha.com

    Integrated Diagnostics Holdings plc (IDGXF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Integrated Diagnostics Holdings plc (IDGXF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Integrated Diagnostics Holdings plc (IDGXF) Q3 2025 Earnings Call Transcript